tbuckley/cabot-search huggingface dataset:
Endoscopic thermal ablation therapies for hepatocellular carcinoma; multi-center study
Authors: H. Sakaguchi, S. Seki, S. Iwai, H. Kadoya, K. Ido, N. Isoda, K. Tsuji, K. Teramoto, M. Suzuki, K. Kioka
Journal: Journal of Clinical Oncology (2006)

4147 Background: Differences of efficacy between radiofrequency ablation (RFA) and microwave coagulation (MWC) for hepatocellular carcinoma (HCC) is still unknown. So we performed multi-center study to assess factors contributing to survival among patients treated by endoscopic thermal ablation for single HCC. Methods: 396 patients in six institutions with single HCC who were firstly treated by endoscopic thermal ablation were enrolled in this study and assessed retrospectively. Among 396 patients, 347 were treated under general anesthesia and 49 were treated local anesthesia. 144 were treated by MWC and 252 were treated by RFA. 383 were ablated laparoscopically and 13 were done thoracoscopically. 230 HCCs were located superficial position of liver and 166 were deep position. Classification with Child-Turcotte-Pugh score, the Japan Integrated Staging score, and the Cancer of the Italian Program scoring system were performed. All patients were analyzed survival rates by Kaplan-Meier method and differences among groups were compared by the log-rank test. Results: Five year survival rates of all 396 patients were 63% and ten year survival rates were 42%. Differences between general and local anesthesia were not significant (p = 0.28). Differences between MWC and RFA were not significant (p = 0.77). Location of HCCs were not significant (p = 0.89). Differences among groups classified by Child-Turcotte-Pugh score were significant (p = 0.017). Classification by the Japan Integrated Staging score was not significant (p = 0.24). However, classification by the Cancer of the Italian Program scoring system were significant (p = 0.001). Conclusions: Endoscopic thermal ablation therapies for HCC was effective. Differences of efficacy between RFA and MWC were not found. No significant financial relationships to disclose.
Tyrosine Phosphorylation and p72syk Activation by an Anti-Glycoprotein Ib Monoclonal Antibody
Authors: Mutsumasa Yanabu, Yukio Ozaki, Shosaku Nomura, Tetsuya Miyake, Yasuhiko Miyazaki, Hideo Kagawa, Yoshitaka Yamanaka, Naoki Asazuma, Kaneo Satoh, Shoji Kume, Yutaka Komiyama, Shirou Fukuhara
Journal: Blood (1997)
Randomized Clinical Trial of Induction Therapy Comparing Intensified Daunorubicin with Idarubicin in Patients with Previously Untreated De Novo Acute Myeloid Leukemia (JALSG AML201 Study).
Authors: Shigeki Ohtake, Shuichi Miyawaki, Hiroyuki Fujita, Hitoshi Kiyoi, Katsuji Shinagawa, Noriko Usui, Koichi Miyamura, Miki Nishimura, Yasushi Miyazaki, Kazuhiro Nishii, Tadashi Nagai, Takahisa Yamane, Masafumi Taniwaki, Masatomo Takahashi, Fumiharu Yagasaki, Yukihiko Kimura, Norio Asou, Sumihisa Honda, Kazunori Ohnishi, Tomoki Naoe, Ryuzo Ohno
Journal: Blood (2006)
Ifosfamide and Etoposide as a Salvage Chemotherapy for Small Round Cell Sarcoma
Authors: Shingo Tamura, Yuzo Matsushita, Mamoru Tanaka, Hozumi Kumagai, Shuji Arita, Hiroshi Ariyama, Hitoshi Kusaba, Eishi Baba, Koichi Akashi
Journal: Annals of Oncology (2014)
Gene Acquisitions from Bacteria at the Origins of Major Archaeal Clades Are Vastly Overestimated
Authors: Mathieu Groussin, Bastien Boussau, Gergely Szöllõsi, Laura Eme, Manolo Gouy, Céline Brochier-Armanet, Vincent Daubin
Journal: Molecular Biology and Evolution (2015)

In a recent article, Nelson-Sathi et al. (NS) report that the origins of major archaeal lineages (MAL) correspond to massive group-specific gene acquisitions via HGT from bacteria (Nelson-Sathi et al. 2015. Origins of major archaeal clades correspond to gene acquisitions from bacteria. Nature 517(7532):77-80.). If correct, this would have fundamental implications for the process of diversification in microbes. However, a reexamination of these data and results shows that the methodology used by NS systematically inflates the number of genes acquired at the root of each MAL, and incorrectly assumes bacterial origins for these genes. A reanalysis of their data with appropriate phylogenetic models accounting for the dynamics of gene gain and loss between lineages supports the continuous acquisition of genes over long periods in the evolution of Archaea.
Effect of gefitinib when combined with radiation on human cervical squamous cell carcinoma
Authors: B. M. Sood, A. A. Alfieri, D. Nori, R. A. Britten, C. C. Kan
Journal: Journal of Clinical Oncology (2005)

9659 Purpose: Epithelial growth factor receptor (EGFR) signaling is involved in the proliferation and survival of cancer cells. Gefitinib (Iressa) as an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is implicated in TK activity and autophosphorylation of EGFR. The present studies, investigated the effects of EGFR-TKI with concomitant radiation (RT) on cervical cancer cell responsiveness as a combined therapy. Methods: Exponentially grown cervical carcinoma cells: HT137, HT155 and HELA-S3 in MEM, 10% FBS were chronically incubated with gefitinib (1uM for 3 days) followed by RT (2 - 9Gy). Clonogenic and MTT assays, FACSCan flow cytometric analysis for cellular progression/arrest and apoptotic response by DNA fragmentation (PAGel gel electrophoresis) was performed. Results: Gefitinib alone at (1uM /3days) had marginal toxicities on HT137 and HT155 and HELA cells. Time dependent decrease in survival was apparent with maximum reduction (19–26%) in clonogenicity by 3rd day. Survival of both HT137 and HT155 cells was reduced to ∼0.17 at SF3Gy and 0.07at SF6Gy respectively. This was further augmented when cells were irradiated in the presence of gefitinib to SF3Gy 0.04 and SF6Gy ∼0.005 respectively, demonstrating significant (p≤0.05) radiation-induced interaction at lower dose fractions that was abrogated at higher doses where survival in combined therapies was equivalent. This trend in survival reduction was apparent in HELA cells although to a lesser extent than that observed in HT137 and HT155. Cell cycle analysis for preG1 was consistent with qualitative apoptotic responses on fragmentation columns for drug alone. Maximum response (≥20%) was observed in all cell lines with HT137 cells demonstrating dominate effects from combined treatment at 3day incubation compared to gefitinib alone, with subsequent G2/M blocks increasing between 18–36% for all cell lines. Discussion: Gefitinib (1uM) demonstrates time dependent increase in drug-induced apoptotic effects and inhibition in cell cycle progression in three human cervical squamous carcinoma line evaluated. Gefitinib when combined with irradiation demonstrated enhanced efficacy at lower (<3Gy) radiation dosages and only marginal additive effects when used at RT dosages >3Gy. No significant financial relationships to disclose.
Treatment of Burkitt lymphoma: A single institution’s experience
Authors: T. Patel, N. Drazin, A. Nguyen, H. Hool, R. Agajanian, A. Pakanati, S. Song, N. Feldman, L. Pinter-Brown, L. Powell
Journal: Journal of Clinical Oncology (2005)

6742 Background: Burkitt lymphoma (BL) is one of the clinically aggressive NHLs. McMaster et al. (JCO 9:941–6, 1991) presented an 8-week, 7-drug regimen for aggressive lymphomas, with a CR of 81% for BL. Cabanillas et al (PASCO 2003, abs# 2309, 2003) treated BL with hyper-CVAD plus rituximab, delivered over 32 weeks, with a CR rate of 89%. One year survival, however, is only approximately 60% by these or other regimens. Our medical center serves a largely indigent urban population; we report here a retrospective study of our experience with these two regimens. Methods: Over the past 7 years, 9 cases were identified: median age 42 years (range 26–55); male: female ratio 8:1; HIV infection 6 pts; stage I-II (2 pts); III-IV (7 pts); and ECOG 0–1 (8 pts) and 2 (1 pt). Patients were treated by McMaster regimen (McM), hyper-CVAD, CHOP or EPOC regimens with rituximab at the discretion of the treating physician. Results: Two pts. treated with CHOP achieved a PR; one was unsuccessfully salvaged with EPOCH (died at 3 mos.), and one was successfully salvaged with McM with rituximab (McM+R) (NED at 51 months). One pt. treated with EPOCH+R achieved a PR and failed salvage with McM+R. One pt. treated with hyper-CVAD+R achieved a CR. Four pts. were treated by McM, 1 with and 3 without rituximab, with 3 of 4 achieving a durable. All received CNS prophylaxis. Pt.#5 presented with CNS disease. Pt. #2 suffered a CNS relapse at 17 mos. and was salvaged with high dose MTX. One patient refused therapy. Primary prophylaxis with G-CSF was done throughout. Grade 4 hematological toxicities occurred in all patients; septic deaths occurred only in PR/NR pts. Conclusions: At our institution, 4 of the 6 patients treated with McM regimen had a durable CR. This regimen remains an attractive option for the treatment of BL. No significant financial relationships to disclose.
A phase II study of VEGF trap (aflibercept) in patients with radioactive iodine-refractory, positron emission tomography (PET) positive thyroid carcinoma.
Authors: E. J. Sherman, A. L. Ho, S. Haque, R. A. Ghossein, D. M. Lisa, H. Schöder, M. S. Baum, A. R. Shaha, R. M. Tuttle, D. G. Pfister
Journal: Journal of Clinical Oncology (2010)

5587 Background: Historically, systemic therapy for RAI-refractory thyroid cancer has been understudied, but activity has recently been seen with multi-targeted tyrosine kinase inhibitors (TKIs) that act partly as angiogenesis inhibitors. VEGF Trap (VT) is a recombinantly- produced fusion protein consisting solely of human sequences for vascular endothelial growth factor receptor (VEGFR) extracellular domains and human immunoglobulin G1. Methods: The study was a single institution, phase II, Simon 2-stage design ([21->41 patients (pts)] based on major response rate/6 month progression-free survival as the primary endpoints. Eligible pts have progressive, RAI- refractory/fluorodeoxyglucose (18-F)-avid, recurrent/metastatic, non-medullary, non-anaplastic thyroid cancer; RECIST measurable disease; and adequate organ/marrow function. VT 4 mg/kg IV was administered every 14 days. This abstract provides results from the completed first stage of accrual. Results: 21 pts have been enrolled between 8/22/08 and 1/20/09: female-62%; median age-65 years; histology-papillary (14)/follicular (2)/Hürthle (5). Grade 4-5 adverse events at least possibly related to drug documented to date: grade 5 - none: grade 4 (one of each) – proteinuria; thrombotic microangiopathy; lymphopenia; confusion/posterior reversible encephalopathy syndrome; myocardial infarction. Evaluation of best response: complete or partial (0); stable disease (18); progression (3). 10/18 pts with stable disease remained on study for > 6 months, 3/18 pts for > 12 months; the median duration of stable disease on treatment is 178 days. Conclusions: Despite major response rates being reported with TKIs that are angiogenesis inhibitors, no responses have been seen with VT to date. However, durable stable disease is common and toxicity is manageable. Accrual to the second stage of the study continues. (Study funded by grant N01 CM 62206.) Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration sanofi-aventis
Hemodynamic response on sleep disordered breathing in obese subjects during N2 stage
Authors: Dina Grencho, Richard Staats, Dina Fernandes, Susana Moreira, Paula Pinto, Antonio Almeida, João Valença
Journal: European Respiratory Journal (2014)

Introdution :Obstructive sleep apneas(OSA) are associated with an increased risk for cardio-vascular diseases e.g. arterial hypertension. However, the impact of morbid obesity and alveolar hypoventilation is not yet fully understood. In this preliminary data, we compare the hemodynamic values during N2 sleep in 16 Obese patients with OSA and/or non-obstructive Hypoventilation.   Methods:  We analyzed 53periods of continue N2 sleep, in 4groups, according oxygen desaturation index(ODI) and percentage of SpO2 15T3=OSA (ODI>15&T90   Results:     Discussion: We found significant differences between the 3 groups with sleep disordered breathing(SDB) when compared to obese controls (group0). These results indicate a possible impact of SDB on the hemodynamic values independent of morbid obesity.
Cytomegalovirus Isolations From Cell Cultures Derived From Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: C Desgranges, J M Seigneurin, M Baccard, S Nejmi
Journal: JNCI Journal of the National Cancer Institute (1983)

Cytomegalovirus (CMV) was isolated in cell cultures derived from 2 of 11 nasopharyngeal carcinoma (NPC) biopsy specimens from North African patients. All these cases were Epstein-Barr virus (EBV)-associated NPC. Morphologic cytopathic changes and viral replication not associated with EBV were observed after 2 months in culture. Virus identification was achieved by immunofluorescence studies, and cell culture antigens were tested by the use of complement fixation and indirect hemagglutination. All these NPC patients had been infected by herpes simplex virus, varicella-zoster virus, and CMV, but the antibody titers determined by complement fixation and immunofluorescence were normal. CMV, which is not associated with this cancer, could nevertheless favor carcinogenesis in facilitating fusion between epithelial cells and EBV-positive lymphocytes.
Thoracic splenosis - Case series and review of the literature
Authors: Nissim Arish, Ariel Rockach, Naama Bogot, Irith Hadas-Halperen, Gabriel Izbicki
Journal: European Respiratory Journal (2012)

Introduction : Splenosis is a rare finding of ectopic splenic tissue found within the thoracic cavity, abdomen or peritoneal cavity. In thoracic splenosis the splenic tissue most often grows in the form of a nodule and the auto-transplantation is usually caused by a previous penetrating or blunt trauma to the thoracic-abdominal region, resulting in splenic rupture.

Cases : We present three cases of thoracic splenosis. All the patients were Caucasians male aged 40-63 presenting with pleural masses that mimicked malignancy, who were eventually diagnosed as thoracic splenosis. All of them had a history of traumatic event to their upper abdomen which occurred 13-40 years ago resulting in splenectomy.

Methods: We made a Medline search in order to find all the cases of thoracic splenosis. We reviewed the cases in order to specify this rare condition.

Results: we found 39 case reports of patients diagnosed with thoracic splenosis. In the majority of the cases the patients are asymptomatic and are incidentally diagnosed with left hemithorax pulmonary lesions found via chest radiography or thoracic computed tomography. The average period of diagnosing thoracic splenosis from the time of trauma is roughly 21 years and ranges from 6 to 46 years. The diagnosis is challenging and the patients usually undergo extensive workout including surgical biopsy

Conclusion : We conclude that splenosis is a rare entity but one should think about this possibility in a patient with a left thoracic mass and a history of abdominal trauma, splenic rupture and splenectomy.
A prospective study of early gastrointestinal complications of bone marrow transplantation at AIIMS, New Delhi, India
Authors: G. M. Bhat, L. Kumar
Journal: Journal of Clinical Oncology (2008)

20729 Background: The study was conducted with the purpose of finding clinical profile of early gastrointestinal complications at this center. Methods: Seventy consecutive subjects, who were subject to bone marrow transplant from October 2002 to September 2004 were prospectively studied. The gastrointestinal complications were followed in first 100 days of transplant and recorded in a pre-determined format. NCI criteria version 3 or where necessary other standard criteria were used for grading/staging of complications. Results: Study population comprised of 23 allo-transplant (with 3-non-myelablative procedures) and 47 auto-transplant subjects. The allo-transplant group included 18 males and 5 females with age ranged from 4–42 years (median-23). The auto-transplant patients included 25 males and 12 females, age ranged from 4 to 68 years (median-47). Allo-transplant cases included- CML.-CP- 9, CML.-AC-2, CML.-BC-2, AML-4, aplastic anemia-3, Hurlers syndrome-2, thalassemia major-1 and auto-transplant group included -MM-29, HD-8, NHL-6, AML-3, neuroblastoma-1. BuCy (busulphan+cyclophosphamide) and high dose melphalan were the main preparatory regimens. Gastrointestinal complications: nausea and vomiting in 19 (82.60%), mucositis- 20 (86.95%), diarrhea- 15 (65.21%), veno-ocllusive disease (VOD)- 3 (13.04%) and acute pancreatitis- 1 (4.34%) in allo-transplant group. Nausea and vomiting occured 36 (76.59%), mucositis- 46 (97.88%) diarrhea- 39 (82.98%), VOD- 5 (10.64%) in auto- transplant subjects. Majority of patients had grade II vomiting and diarrhea in both groups. Mucositis lasted: range - 4–23 days (median 10.6) in allo-, 1–20 days (median 11) days in auto-BMT group. Onset of VOD was on day 13.5 (range 6–21) in allo-BMT and on day 9 (range 5–22) in auto-BMT cases. VOD was of Bearman grade I (n-1), II (n-1), III (n-1) in allo-group and I (n-1). II (n-2), III (n-1) in auto-group. AGVHD involved gut in 3 and liver in 1 case of allo-BMT-group. Gastrointestinal tract was the source of sepsis in- 15 (21.43%) with 7 cases of enterocolitis, 8 of parianal sepsis and 1 of clostridium difficili. Conclusion: Clinical profile of early gastrointestinal complications in this eastern center was similar to that reported in world literature. No significant financial relationships to disclose.
Studies on the Biological Interrelationships of Folic Acid, Citrovorum Factor, and the Antimetabolite, Aminopterin&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: Abraham Goldin, Ph. D., Ezra M. Greenspan, M. D., John M. Venditti, B. S., Emanuel B. Schoenbach, M. D.
Journal: JNCI Journal of the National Cancer Institute (1952)

Studies on the Biological Interrelationships of Folic Acid, Citrovorum Factor, and the Antimetabolite, Aminopterin Get access Abraham Goldin, Ph. D., Abraham Goldin, Ph. D. Clinical Research Unit of the National Cancer Institute, U. S. Public Health Service Hospital, and the Department of Preventive Medicine, The Johns Hopkins University School of Medicine5, Baltimore, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Ezra M. Greenspan, M. D., Ezra M. Greenspan, M. D. Clinical Research Unit of the National Cancer Institute, U. S. Public Health Service Hospital, and the Department of Preventive Medicine, The Johns Hopkins University School of Medicine5, Baltimore, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar John M. Venditti, B. S., John M. Venditti, B. S. Clinical Research Unit of the National Cancer Institute, U. S. Public Health Service Hospital, and the Department of Preventive Medicine, The Johns Hopkins University School of Medicine5, Baltimore, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Emanuel B. Schoenbach, M. D. Emanuel B. Schoenbach, M. D. Clinical Research Unit of the National Cancer Institute, U. S. Public Health Service Hospital, and the Department of Preventive Medicine, The Johns Hopkins University School of Medicine5, Baltimore, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 12, Issue 5, April 1952, Pages 987–1002, https://doi.org/10.1093/jnci/12.5.987 Published: 01 April 1952 Article history Received: 12 October 1951 Published: 01 April 1952
<i>JAMA</i>Welcomes the US Preventive Services Task Force
Authors: Howard Bauchner, Phil B. Fontanarosa, Robert M. Golub
Journal: JAMA (2016)

Albert L. Siu, MD, MSPH; and the US Preventive Services Task Force (USPSTF); Kirsten Bibbins-Domingo, PhD, MD, MAS; David C. Grossman, MD, MPH; Linda Ciofu Baumann, PhD, RN, APRN; Karina W. Davidson, PhD, MASc; Mark Ebell, MD, MS; Francisco A. R. García, MD, MPH; Matthew Gillman, MD, SM; Jessica Herzstein, MD, MPH; Alex R. Kemper, MD, MPH, MS; Alex H. Krist, MD, MPH; Ann E. Kurth, PhD, RN, MSN, MPH; Douglas K. Owens, MD, MS; William R. Phillips, MD, MPH; Maureen G. Phipps, MD, MPH; Michael P. Pignone, MD, MPH
Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer.
Authors: Yusuke Katayama, Toru Aoyama, Masahiro Asari, Masaaki Murakawa, Koichiro Yamaoku, Amane Kanazawa, Akio Higuchi, Manabu Shiozawa, Makoto Akaike, Makoto Ueno, Manabu Morimoto, Naoto Yamamoto, Takaki Yoshikawa, Yasushi Rino, Munetaka Masuda, Soichiro Morinaga
Journal: Journal of Clinical Oncology (2015)

471 Background: The factors which affect the six-month continuation of adjuvant chemotherapy with S-1 have not been fully evaluated in pancreatic cancer. The objective of this retrospective study was to clarify the risk factors for the discontinuation of S-1 adjuvant chemotherapy after six months of treatment. Methods: The study included patients who underwent curative surgery for pancreatic cancer, were diagnosed with stage II or III disease, had a serum creatinine level &lt; 1.2 mg/dl and received adjuvant S-1 between June 2007 and March 2014. Results: Forty patients were eligible for the present study. A comparison of the six-month continuation stratified by each clinical factor using the log-rank test revealed a significant difference in the creatinine clearance (CCr) between the patients who continued and discontinued the treatment. A CCr of 60 ml/min was regarded as a critical point. The uni- and multivariate Cox’s proportional hazard analyses demonstrated that the CCr was the only significant independent predictive factor. The six-month continuation rate was 70.8% in the patients with a CCr &gt; 60 ml/min, and was 25.0% in patients with a CCr &lt; 60 ml/min (P=0.008). The patients with a CCr &lt; 60 ml/min developed adverse events more frequently and earlier than those with a CCr &gt; 60 ml/min. Conclusions: A CCr &lt; 60 ml/min was a significant risk factor for the six-month discontinuation of S-1 adjuvant chemotherapy in pancreatic cancer patients, even though the renal function was judged to be normal based on the serum creatinine level. Careful attention is therefore required to improve the S-1 continuation in patients with a CCr &lt; 60 ml/min.
Acute haematogenous osteomyelitis in children
Authors: O Carmody, D Cawley, M Dodds, P Connolly
Journal: BMJ (2014)

have alerted us to an error.They would like to correct the statement "Benzylpenicillin or a cephalosporin should be added in children not immunised against H influenzae," which is located in the third paragraph of the section "How is osteomyelitis treated?"This sentence should have read:"A second or third generation cephalosporin (e.g.cefuroxime or cefotaxime) should be added in children not immunised against H influenzae.
Brief Communication: Growth of Human Normal and Neoplastic Mammary Tissues in the Cleared Mammary Fat Pad of the Nude Mouse2
Authors: H. C. Outzen, R. P. Custer
Journal: JNCI Journal of the National Cancer Institute (1975)

Journal Article Brief Communication: Growth of Human Normal and Neoplastic Mammary Tissues in the Cleared Mammary Fat Pad of the Nude Mouse Get access H. C. Outzen, H. C. Outzen Search for other works by this author on: Oxford Academic PubMed Google Scholar R. P. Custer R. P. Custer Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 55, Issue 6, December 1975, Pages 1461–1466, https://doi.org/10.1093/jnci/55.6.1461 Published: 01 December 1975 Article history Received: 07 March 1975 Accepted: 30 July 1975 Published: 01 December 1975